The company is advancing therapeutic candidates for rare disorders in nephrology, hepatology, and metabolism. They are also sponsoring genetic testing to improve diagnosis for children with cholestasis and partnering with patient advocacy organizations. Additionally, Travere Therapeutics ensures broad access and education for its FDA-approved therapies. Their pipeline candidate, sparsentan, is in late-stage development for rare kidney disorders that often lead to end-stage kidney disease. Based in San Diego, California, Travere Therapeutics is dedicated to addressing the needs of patients living with rare diseases.